Increased release of sMD-2 during human endotoxemia and sepsis: a role for endothelial cells

Mol Immunol. 2008 Jun;45(11):3268-77. doi: 10.1016/j.molimm.2008.02.014. Epub 2008 Apr 1.

Abstract

MD-2 is the crucial cofactor of TLR4 in the detection of LPS. Here, we show that soluble MD-2 (sMD-2) circulates in plasma of healthy individuals as a polymeric protein. The total amount of sMD-2 in septic plasma was strongly elevated and contained both sMD-2 polymers and monomers, the latter representing the putative biologically active form of MD-2. Moreover, during experimental human endotoxemia, the monomeric and total sMD-2 content in plasma increased with the kinetics of an acute phase protein. The increase in sMD-2 monomers was paralleled by enhanced TLR4 costimulatory activity. The presence of functional sMD-2 during endotoxemia and sepsis was confirmed by immunodepletion. Immunohistochemistry revealed that MD-2 expression in septic patients was strongly enhanced on endothelium and multiple inflammatory cells in lung and liver. In vitro studies showed that sMD-2 release appears to be restricted to endothelial cells and dendritic cells. Release of sMD-2 by endothelial cells was strongly enhanced by LPS and TNF-alpha stimulation. Taken together, this study demonstrates the increase of both circulating polymeric and functional monomeric sMD-2 during endotoxemia and sepsis, and evidence is provided that the endothelium is involved in this process.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Case-Control Studies
  • Endothelial Cells / drug effects
  • Endothelial Cells / immunology
  • Endothelial Cells / metabolism*
  • Endothelial Cells / pathology
  • Endotoxemia / immunology
  • Endotoxemia / metabolism*
  • Female
  • Hematopoietic System / cytology
  • Hematopoietic System / drug effects
  • Humans
  • Kinetics
  • Lipopolysaccharides / pharmacology
  • Liver / drug effects
  • Liver / immunology
  • Liver / pathology
  • Lung / drug effects
  • Lung / immunology
  • Lung / pathology
  • Lymphocyte Antigen 96 / blood
  • Lymphocyte Antigen 96 / metabolism*
  • Male
  • Middle Aged
  • Sepsis / blood
  • Sepsis / immunology
  • Sepsis / metabolism*
  • Solubility / drug effects
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Lipopolysaccharides
  • Lymphocyte Antigen 96
  • Tumor Necrosis Factor-alpha